SAN DIEGO / May 22, 2025 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45 th Annual Growth Stock Conference, Wednesday, June 4, 2025... Read More

Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening Strong execution on cost-savings initiatives driving improved margins and profitability Company maintains full-year 2025 financial guidance First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million,... Read More

SAN DIEGO / Apr 23, 2025 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following... Read More

Elevating laboratory efficiency and patient care SAN DIEGO / Mar 10, 2025 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager... Read More

SAN DIEGO / Feb 24, 2025 / Business Wire / QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46 th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of... Read More

Strong finish to 2024 with continued progress in cost-savings initiatives to drive adjusted EBITDA margin expansion in 2025 and beyond Company issues full-year 2025 financial guidance Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported Non-respiratory revenue was $565 million, which was flat compared to the prior year period due to... Read More

Top-line Results In Line with Expectations; Company Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 SAN DIEGO / Jan 13, 2025 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary... Read More

SAN DIEGO / Dec 31, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43 rd Annual J.P. Morgan Healthcare Conference. The Company’s presentation is scheduled for Monday, January 13,... Read More

Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board SAN DIEGO / Dec 10, 2024 / Business Wire / QuidelOrtho Corporation ( Nasdaq: QDEL ) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro... Read More

SAN DIEGO / Nov 19, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling... Read More

SAN DIEGO / Nov 19, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by Carlyle Partners VI Cayman Holdings, L.P. (the “Selling Stockholder”) of 8,260,183... Read More

Company reinstates 2024 financial guidance Drives cost-savings and growth initiatives Strengthens leadership team and aligns organization for improved effectiveness Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) Reported revenue was $727 million Recurring revenue 1 was $598 million as reported with no significant change in constant currency, excluding COVID-19 and U.S. Donor... Read More

SAN DIEGO / Oct 28, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences. UBS Global... Read More

SAN DIEGO / Oct 17, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its third quarter 2024 ended September 29, 2024, after the market close on Thursday, November 7, 2024.... Read More

Jonathan Siegrist appointed as EVP of R&D and CTO SAN DIEGO / Oct 09, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and... Read More

SAN DIEGO / Sep 10, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho’s human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture.... Read More

QuidelOrtho Receives FDA 510(k) Clearance for its VITROS Syphilis Assay SAN DIEGO / Aug 29, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its VITROS syphilis assay as part of its menu, strengthening QuidelOrtho’s... Read More

SAN DIEGO / Aug 19, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend two upcoming investor conferences. Morgan Stanley 22 nd Annual Global Health Conference – New York, NY On Thursday,... Read More

$100 million in annualized cost-savings initiatives will benefit second half 2024 and first half 2025 Strong progress on business review and refocusing R&D investments on core growth areas Second quarter 2024 revenue was $637 million, as reported: Total recurring revenue 1 grew 3% as reported and 5% in constant currency compared to the prior year period, excluding COVID-19 revenue and U.S. Donor Screening revenue YTD 2024... Read More

SAN DIEGO / Jul 17, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2024 ended June 30, 2024, after the market close on Wednesday, July 31, 2024. Following... Read More

SAN DIEGO / May 23, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 44 th Annual William Blair Growth Stock Conference on June 5, 2024, in Chicago,... Read More

Center expands distribution footprint and reduces waste with greener packaging SAN DIEGO / May 15, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) has launched a second state-of-the-art United States distribution center in Pedricktown, New Jersey. This strategic endeavor epitomizes QuidelOrtho’s commitment to... Read More

Global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue Cost reduction initiatives well underway, headcount reductions expected to deliver approximately $100 million in annualized savings Company suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer First Quarter 2024 Results and Recent Highlights Revenue was $711... Read More

Brings More Than Two Decades of Leadership Experience in the In-Vitro Diagnostics Industry SAN DIEGO / May 02, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and... Read More

SAN DIEGO / Apr 17, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today it will report its financial results for its first quarter ended March 31, 2024, after the market close on Wednesday, May 8, 2024. Following the release... Read More

Helping hospital and emergency room customers respond to the critical demand for enhanced opioid testing SAN DIEGO / Apr 10, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System... Read More

Test Delivers on Company Commitment to Advance the Power of Diagnostics to Empower Patients with Rapid Results in Just 10 Minutes Savanna® RVP4+ Assay Research and Development Update SAN DIEGO / Apr 02, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and... Read More

Aiding in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women SAN DIEGO / Mar 06, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in... Read More

SAN DIEGO / Feb 26, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45 th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.... Read More

The Board of Directors has terminated President and Chief Executive Officer, Douglas Bryant and appointed, on an interim basis, Michael Iskra as Chief Executive Officer and Robert Bujarski as President SAN DIEGO / Feb 21, 2024 / Business Wire / The Board of Directors (the “Board”) of QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”) has made significant decisions aimed to enhance operational efficiency,... Read More

Strong momentum in Labs business, with solid non-respiratory business growth and market share gains in industry-leading respiratory point-of-care portfolio Fourth Quarter 2023 Results and Highlights Revenue was $743 million, as reported: Non-respiratory revenue increased by 9% as reported and in constant currency Respiratory revenue decreased by 49% as reported and in constant currency GAAP net cash provided by operating... Read More

SAN DIEGO / Jan 23, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Tuesday, February 13,... Read More

SAN DIEGO / Dec 22, 2023 / Business Wire / QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA,... Read More

Savanna delivers results in 25 minutes or less, improves clinical care, provides cost savings and delivers sample-to-result molecular testing across all laboratory settings SAN DIEGO / Dec 20, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) , a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received... Read More

SAN DIEGO / Nov 16, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023. Douglas Bryant, President and Chief... Read More

Highlights Third quarter revenue was $744 million, as reported, driven by strong respiratory demand and continued strength in non-respiratory businesses Non-respiratory revenue increased by 2% as reported and in constant currency, compared to the prior year period, driven by growth in the Labs business, which continues to perform to expectations Respiratory revenue decreased by 21% as reported and in constant currency,... Read More

Global Lyme Alliance (GLA), a leading nonprofit, produces chronic Lyme PSA with generous sponsorship from QuidelOrtho to ensure the broad visibility of this crucial message. STAMFORD, Conn. , Oct. 17, 2023 /PRNewswire/ -- In an inspiring and emotional display of solidarity for Lyme disease awareness, a striking public service announcement (PSA) has taken center stage in the heart of New York City's Times Square. The PSA, is... Read More

Earlier-than-expected demand for respiratory products in core markets drives strong preliminary performance Company to report third quarter 2023 financial results on November 1, 2023 SAN DIEGO / Oct 12, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and... Read More

SAN DIEGO / Sep 21, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the... Read More

SAN DIEGO / Aug 28, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 12, 2023. Douglas... Read More

Highlights Second quarter revenue of $665.1 million increased by 8% as reported with non-respiratory revenue up 3% on a supplemental combined basis (up 4% in constant currency) and respiratory revenue down 74% on a supplemental combined basis Non-respiratory revenue driven by 9% constant currency growth in Labs business unit Second quarter GAAP loss per share of $(0.80); adjusted EPS of $0.26, an 88% decrease from prior year... Read More

Company receives top customer rating in the 2023 IMV ServiceTrak™ Awards SAN DIEGO / Jul 25, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has earned the No. 1 ranking in the diagnostics industry for Overall Customer... Read More

Strategic partnership will add middleware and data management solutions across the company’s diagnostics portfolio SAN DIEGO / Jul 24, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has entered into a software... Read More

SAN DIEGO / Jul 18, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2023 ended July 2, 2023, after the market close on Tuesday, August 8, 2023. Following... Read More

SAN DIEGO / May 23, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the William Blair 43 rd Annual Growth Stock Conference in Chicago, Illinois, on June 6, 2023. A... Read More

Highlights First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental combined basis Growth in non-respiratory revenue for the first quarter was driven by the Labs business unit, primarily due to heightened instrument delivery and testing demand First quarter GAAP EPS... Read More

QuidelOrtho to report first quarter 2023 financial results on May 3, 2023 SAN DIEGO / Apr 13, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the first quarter ended April 2, 2023. The... Read More

The integration of Quidel Corporation and Ortho Clinical Diagnostics joined two powerhouse networks providing leadership insights, professional development and mentoring to QWLN members around the globe SAN DIEGO / Mar 28, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and... Read More

SAN DIEGO / Mar 08, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted a De Novo request from the U.S. Food and Drug Administration (FDA), allowing the company to market its new Sofia® 2 SARS Antigen+ FIA. The Sofia 2... Read More

SAN DIEGO / Mar 02, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference in... Read More

MADISON, Wis. , Feb. 27, 2023 /PRNewswire/ -- ImageMover , a provider of Workflow Services for pharmacies, is proud to announce its partnership with QuidelOrtho (NASDAQ: QDEL), a leading provider of point-of-care diagnostic testing solutions, to bring a comprehensive solution for pharmacist-administered testing for a variety of illnesses, including COVID-19, influenza A+B, Lyme disease, strep throat, and RSV. This... Read More

SAN DIEGO / Feb 15, 2023 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter ended January 1, 2023. The Company reported total revenue for the fourth quarter of 2022 of $866.5 million, a... Read More

QuidelOrtho to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023. The... Read More

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco beginning on January 9, 2023, with a presentation scheduled for 9:00 a.m. PST... Read More